Technical Analysis for AEMD - Aethlon Medical, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -9.77% | |
| Wide Bands | Range Expansion | -9.77% | |
| Down 3 Days in a Row | Weakness | -9.77% | |
| Down 4 Days in a Row | Weakness | -9.77% |
| Alert | Time |
|---|---|
| Down 5% | about 6 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| Down 2 % | about 6 hours ago |
| Down 1% | about 6 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/26/2024
Aethlon Medical, Inc. Description
Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company's Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It is also developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.
Classification
Sector: Technology
Industry: Scientific & Technical Instruments
Keywords: Medicine Cancer Biology Infectious Diseases Treatment Of Cancer Neurological Disorders Coronavirus Hepatitis Viruses Immunodeficiency Urological Disorders Virus Antiviral Drug Exosome Sepsis Therapeutic Device Vesicles
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.0 |
| 52 Week Low | 0.3704 |
| Average Volume | 5,413,954 |
| 200-Day Moving Average | 1.56 |
| 50-Day Moving Average | 0.80 |
| 20-Day Moving Average | 0.57 |
| 10-Day Moving Average | 0.59 |
| Average True Range | 0.10 |
| RSI (14) | 34.64 |
| ADX | 24.54 |
| +DI | 27.60 |
| -DI | 24.01 |
| Chandelier Exit (Long, 3 ATRs) | 0.54 |
| Chandelier Exit (Short, 3 ATRs) | 0.67 |
| Upper Bollinger Bands | 0.73 |
| Lower Bollinger Band | 0.41 |
| Percent B (%b) | 0.14 |
| BandWidth | 56.99 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.53 | ||||
| Resistance 3 (R3) | 0.54 | 0.52 | 0.52 | ||
| Resistance 2 (R2) | 0.52 | 0.50 | 0.52 | 0.52 | |
| Resistance 1 (R1) | 0.49 | 0.49 | 0.48 | 0.48 | 0.51 |
| Pivot Point | 0.47 | 0.47 | 0.46 | 0.46 | 0.47 |
| Support 1 (S1) | 0.43 | 0.45 | 0.42 | 0.42 | 0.39 |
| Support 2 (S2) | 0.41 | 0.43 | 0.41 | 0.38 | |
| Support 3 (S3) | 0.38 | 0.41 | 0.38 | ||
| Support 4 (S4) | 0.37 |
